A natural consequence of this process will be the identification of generic and specific targets: the former will apply to a broad range of tumour types (e.g., targeting the DNA damage response) (Helleday et al, 2008) while the latter may only be relevant to a small number of tumours (e.g., EGFR variant III in head and neck cancer and glioblastoma) (Sok et al, 2006; Mukherjee et al, 2009). This evidence concerns the gene EGFR and neoplasm.